On February 12, 2018, Virginia Contract Research Organization Co., Ltd. (VCRO) successfully obtained a permit from the US FDA to launch a first-in-human Phase I trial for a new chemical entity in rare disease. The targeted indication is an orphan neurological disorder.
Congratulations! VCRO obtained a permit from the US FDA to launch the clinical development of a NCE in rare disease!
On February 12, 2018, Virginia Contract Research Organization Co., Ltd. (VCRO) successfully obtained a permit from the US FDA to launch a first-in-human Phase I trial for a new chemical entity in rare disease. The targeted indication is an orphan neurological disorder.